Draft:David Zhang
From Wikipedia, the free encyclopedia
David Zhang is an American bioengineer, computational biologist, and entrepreneur. He is the founder and chief executive officer (CEO) of Biostate AI, a biotechnology company focused on applying generative artificial intelligence to multi-omics and individualized health analysis.[1] Zhang is a former tenured professor of bioengineering at Rice University[2] and an inventor on over 40 patents, with more than 50 peer-reviewed scientific publications.[3]
 | Review waiting, please be patient.
This may take 8 weeks or more, since drafts are reviewed in no specific order. There are 2,989 pending submissions waiting for review.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
Reviewer tools
|
Early life and education
Zhang received his Bachelor of Science degree in Molecular Biology from the California Institute of Technology (Caltech) in 2005, where he was awarded the Axline Full Merit Scholarship.[4] He later earned a Ph.D. in Computation and Neural Systems from Caltech in 2010 as a Hertz Fellow.[4]
His doctoral research focused on DNA nanotechnology and molecular programming. His Ph.D. thesis, Dynamic DNA Strand Displacement Circuits, consolidated a series of publications that contributed to the development of programmable nucleic acid systems based on DNA strand displacement.[3][4]
Academic career
Following his doctoral studies, Zhang completed postdoctoral research at Harvard Medical School, where he was a Howard Hughes Medical Institute Fellow of the Life Sciences Research Foundation and worked at the Wyss Institute for Biologically Inspired Engineering.[4]
In 2013, Zhang joined Rice University as an assistant professor of bioengineering and was promoted to associate professor in 2019.[5] During his academic tenure, he served as principal investigator or co-principal investigator on multiple NIH R01 grants and Cancer Prevention and Research Institute of Texas (CPRIT) research awards, totaling over US$12 million in funding.[5]
Zhang’s research focused on nucleic acid bioengineering, genome and transcriptome profiling technologies, and molecular diagnostics.[5]
Research
Zhang’s research has focused on nucleic acid bioengineering and the development of genome- and transcriptome-level profiling technologies, with applications in molecular diagnostics for cancer, genetic disorders, autoimmune diseases, and organ transplant rejection.[5]
At Rice University, Zhang led the Nucleic Acid Bioengineering Laboratory, where his group developed nucleic acid–based technologies for noninvasive diagnostics and precision medicine. Research from his laboratory was published in high-impact, peer-reviewed journals and reported by institutional science news outlets.[6]
Zhang’s research has been supported by the National Institutes of Health and the Cancer Prevention and Research Institute of Texas, and his publications have been cited in peer-reviewed scientific literature in the fields of bioengineering, genomics, and DNA nanotechnology.[3]
Awards and honors
Zhang has received several national and institutional honors recognizing his contributions to bioengineering and biomedical research. In 2006, he was named a Hertz Fellow, a highly selective fellowship awarded to early-career scientists and engineers.[4]
He later received the NIH K99/R00 Pathway to Independence Award from the National Institute of Biomedical Imaging and Bioengineering, supporting the transition of promising researchers to independent faculty positions.[7]
In 2008, Zhang received the Grubstake Award for New Technology Development from the California Institute of Technology, which supports early-stage translational research and technology commercialization.[8]
Zhang was also awarded a Life Sciences Research Foundation Fellowship, which supports postdoctoral researchers in the life sciences.[9]
In 2019, Zhang received the Presidential Early Career Award for Scientists and Engineers (PECASE), awarded by the United States Department of Health and Human Services, the highest U.S. government honor for early-career scientists and engineers.[5]
Entrepreneurship
Zhang is a co-founder of NuProbe Global, a biotechnology company focused on the commercialization of molecular diagnostic technologies originating from academic research.[5] He previously served as co-founder and chief executive officer of the company’s U.S. operations.[5]
In 2023, Zhang co-founded Biostate AI, where he serves as chief executive officer.[10] The company focuses on developing generative artificial intelligence systems for multi-omics data integration, operating at the intersection of artificial intelligence, genomics, and biomedical research.[10]
Zhang has also held leadership and advisory roles in the technology and investment sector, including serving as a director at Celesium Capital, a venture capital firm.[11]
Publications and patents
Zhang is an inventor on more than 40 issued and pending patents related to molecular diagnostics and nucleic acid technologies.[4]
He has authored or co-authored over 50 peer-reviewed scientific publications in the fields of bioengineering, DNA nanotechnology, and genomics, including work published in journals within the Nature family and other leading scientific publications.[3]
His academic work has been cited extensively in the scientific literature across multiple disciplines related to molecular biology and biomedical engineering.[3]